Very high efficacy of intermediate-dose cytarabine in combination with G-CSF as a second-line mobilization of hematopoietic stem cells.

作者信息

Kruzel Tomasz, Sadus-Wojciechowska Maria, Najda Jacek, Czerw Tomasz, Glowala-Kosinska Magdalena, Holowiecki Jerzy, Giebel Sebastian

出版信息

Int J Hematol. 2012 Aug;96(2):287-9. doi: 10.1007/s12185-012-1135-5. Epub 2012 Jul 14.

DOI:10.1007/s12185-012-1135-5

PMID:22797877

Abstract

摘要

相似文献

Very high efficacy of intermediate-dose cytarabine in combination with G-CSF as a second-line mobilization of hematopoietic stem cells.

Int J Hematol. 2012 Aug;96(2):287-9. doi: 10.1007/s12185-012-1135-5. Epub 2012 Jul 14.

Increased Efficacy of Stem Cell Chemomobilization with Intermediate-Dose Cytarabine Plus Granulocyte Colony-Stimulating Factor (G-CSF) Compared with G-CSF Alone in Patients with Multiple Myeloma: Results of a Randomized Trial.

Biol Blood Marrow Transplant. 2019 Feb;25(2):248-255. doi: 10.1016/j.bbmt.2018.09.023. Epub 2018 Sep 26.

Higher efficacy of intermediate dose cytarabine + G-CSF compared to cyclophosphamide + G-CSF in hematopoietic stem cell mobilization in patients with multiple myeloma.

J Clin Apher. 2020 Aug;35(4):246-254. doi: 10.1002/jca.21784. Epub 2020 Apr 16.

Intermediate doses of cytarabine plus granulocyte-colony-stimulating factor as an effective and safe regimen for hematopoietic stem cell collection in lymphoma patients with prior mobilization failure.

Transfusion. 2015 Apr;55(4):875-9. doi: 10.1111/trf.12906. Epub 2014 Oct 29.

Increased efficacy of intermediate-dose cytarabine + G-CSF compared to DHAP + G-CSF for stem cell mobilization in patients with lymphoma: an analysis by the polish lymphoma research group.

Ann Hematol. 2016 Jan;95(2):263-9. doi: 10.1007/s00277-015-2557-y. Epub 2015 Nov 27.

Intermediate-dose cytarabine plus G-CSF as mobilization regimen for newly diagnosed multiple myeloma and heavily pre-treated patients with hematological and non-hematological malignancies.

Transfus Apher Sci. 2019 Jun;58(3):318-322. doi: 10.1016/j.transci.2019.03.018. Epub 2019 Mar 29.

Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.

Haematologica. 2013 Feb;98(2):172-8. doi: 10.3324/haematol.2012.071456. Epub 2012 Sep 14.

Cytarabine + G-CSF is more effective than cyclophosphamide + G-CSF as a stem cell mobilization regimen in multiple myeloma.

Bone Marrow Transplant. 2019 Jul;54(7):1107-1114. doi: 10.1038/s41409-018-0396-x. Epub 2018 Nov 20.

[Mobilization of peripheral blood stem cells with mitoxantrone and high-dose cytarabine chemotherapy and rhG-CSF in patients with hematopoietic malignancies].

Zhonghua Xue Ye Xue Za Zhi. 2004 Aug;25(8):462-5.

Whole blood harvested after granulocyte-colony stimulating factor (Neupogen) mobilization, and reinfused unprocessed after high-dose melphalan treatment, accelerates hematopoietic recovery in patients with multiple myeloma.

Cancer. 1996 Mar 15;77(6):1073-8. doi: 10.1002/(sici)1097-0142(19960315)77:6<1073::aid-cncr11>3.0.co;2-z.

引用本文的文献

Stem Cell Mobilization Performed with Different Doses of Cytarabine in Plasma Cell Myeloma Patients Relapsing after Previous Autologous Hematopoietic Cell Transplantation-A Multicenter Report by the Polish Myeloma Study Group.

Cancers (Basel). 2024 Jul 19;16(14):2588. doi: 10.3390/cancers16142588.

Evaluation of efficacy and safety in the use of cytarabine for mobilization of hematopoietic stem cells in a reference hospital in northeastern Brazil.

Hematol Transfus Cell Ther. 2024 Oct-Dec;46(4):428-433. doi: 10.1016/j.htct.2023.08.007. Epub 2023 Oct 29.

本文引用的文献

European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization.

Bone Marrow Transplant. 2012 Aug;47(8):1046-50. doi: 10.1038/bmt.2011.216. Epub 2011 Nov 14.

Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells.

Eur J Haematol. 2011 Jun;86(6):488-95. doi: 10.1111/j.1600-0609.2011.01605.x. Epub 2011 Apr 1.

The EBMT activity survey 2009: trends over the past 5 years.

Bone Marrow Transplant. 2011 Apr;46(4):485-501. doi: 10.1038/bmt.2011.11. Epub 2011 Feb 28.

Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens.

Bone Marrow Transplant. 2011 May;46(5):627-35. doi: 10.1038/bmt.2010.320. Epub 2011 Jan 10.

Improving stem cell mobilization strategies: future directions.

Bone Marrow Transplant. 2009 Feb;43(3):181-95. doi: 10.1038/bmt.2008.410. Epub 2009 Jan 12.

Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.

Biol Blood Marrow Transplant. 2008 Sep;14(9):1045-1056. doi: 10.1016/j.bbmt.2008.07.004.

Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H.

Leukemia. 2004 Jan;18(1):57-62. doi: 10.1038/sj.leu.2403190.

Bone Marrow Transplantation: Prognostic Factors of Peripheral Blood Stem Cell Mobilization with Cyclophosphamide and Filgrastim (r-metHuG-CSF): The CD34+ Cell Dose Positively Affects the Time to Hematopoietic Recovery and Supportive Requirements after High-Dose Chemotherapy.

Hematology. 1999;4(3):195-209. doi: 10.1080/10245332.1999.11746443.

Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy.

J Clin Oncol. 2000 Mar;18(6):1360-77. doi: 10.1200/JCO.2000.18.6.1360.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验